Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23115 | 0.82 | CA2 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL906203 | 0.76 | NPC1 (0.53) | MAPTALDH1A1HPGDL3MBTL1MEN1 | |
| SCHEMBL7001144 | 0.76 | KDM4E (0.43) | MAPTL3MBTL1RAB9AKDM4EPRSS1 | |
| SCHEMBL8256686 | 0.75 | L3MBTL1 (0.72) | MAPTALDH1A1HPGDL3MBTL1MEN1 | |
| SCHEMBL858361 | 0.74 | FDPS (0.50) | FDPSMAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL10187277 | 0.74 | MAPT (0.66) | FDPSMAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL6736811 | 0.73 | NR5A1 (0.46) | ALDH1A1HPGD | |
| SCHEMBL14930189 | 0.72 | INPPL1 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13634485 | 0.72 | L3MBTL1 (0.50) | FDPSCA2MAPTALDH1A1HPGD | |
| SCHEMBL290040 | 0.72 | CA12 (0.71) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | FDPS 539/4885CA12 2439/4885CA1 2861/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | FDPS 539/4885CA12 2439/4885CA1 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.